Human Papillomavirus Vaccine (HPV) Market Overview by Recent Opportunities, Growth Size, Regional Analysis and Forecasts to 2027
The global human papillomavirus vaccine (HPV) market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). There are more than 100 HPV, among which 14 are cancer-causing. According to the WHO, HVP 16 and 18 types are responsible for around 70% of cervical cancer and pre-cancerous cervical lesions. The rising incidences of HPV associated cancers of the anus, vulva, vagina, penis, and oropharynx and increasing demand for prevention of these infections are the major factors that are augmenting the growth of the market during the forecast period. Moreover, government initiatives for HPV vaccination programs are anticipated to boost the market growth during the forecast period. Since June 2020, around 55% of the WHO Member States have introduced HPV vaccination. Furthermore, increasing healthcare infrastructure and expenditure in emerging countries is expected to generate untapped opportunities for the market participants. However, the stringent government regulations associated with manufacturing new vaccines are anticipated to hamper the market growth.
To Request a Sample of our Report on Human
Papillomavirus Vaccine (HPV) Market: https://www.omrglobal.com/request-sample/human-papillomavirus-vaccine-hpv-market
HPV vaccines protect against infection with human papillomaviruses (HPV).
HPV is a group of more than 200 related viruses, of which more than 40 are
spread through direct sexual contact. Among these, two HPV types cause genital
warts, and about a dozen HPV types can cause certain types of cancer associated
with cervical, anal, oropharyngeal, penile, vulvar, and vaginal. In order to
maintain a strong position in the market, these market players are adopting
various strategic moves, such as product launches, partnerships and
collaborations, and mergers and acquisitions.
Recent Developments:
·
In July 2020, the US Food and Drug Administration
(FDA) approved an expanded indication for Merck’ Gardasil 9, a human
papillomavirus (HPV) nine-valent vaccine, for the prevention of oropharyngeal
and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and
58.
·
In March 2020, the HPV vaccine, Cecolin by Innovax
was officially accepted by the WHO for the prequalification evaluation.
Market Coverage
• The market number
available for – 2020-2027
• Base year- 2020
• Forecast period-
2021-2027
• Segment Covered-
·
By Type
·
By Distribution Channel
• Regions covered-
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
·
Competitive Landscape: Merck & Co., Inc., GlaxoSmithKline Plc, and
Sanofi S.A., among others.
(Get 15% Discount on Buying this Report)
A
full Report of Human Papillomavirus Vaccine (HPV) Market is Available @ https://www.omrglobal.com/industry-reports/human-papillomavirus-vaccine-hpv-market
Global HPV Vaccine Market Report by Segment
By Type
• Bivalent
• Polyvalent
By Distribution Channel
•
Hospitals
•
Clinics
·
Government Entities
Global HPV Vaccine Market by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment